https://acrobat.adobe.com/id/urn:aaid:sc:US:1ec3bc5d-3965-4098-a1aa-f61b7a691bb0
The 14th International ATP1A3 in Disease Symposium was held September 25-26, 2026 at the Paris Brain Institute (Institut du Cerveau) on the campus of La Pitié-Salpêtrière Hospital in Paris, France. The two-day program, hosted by the French AHC Foundation, brought together research on the full range of ATP1A3-related disorders, including alternating hemiplegia of childhood (AHC) and rapid-onset dystonia parkinsonism (RDP). Six scientific sessions covered long-term health, disease mechanisms, and treatments, with contributions from families and patient organizations throughout the meeting. There were 191 registered attendees (174 in-person; 17 online) from 21 different countries. A central theme was the need to connect scientific advances with changes that matter in daily life. Researchers reported progress in measuring symptoms, understanding how ATP1A3 variants affect cells, and testing treatments. A controlled study of oxygen for AHC attacks and advances in genetic therapies were important highlights. Many findings remain preliminary, and the genetic treatments discussed are still being developed in laboratory models.